Page last updated: 2024-11-04

norvaline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

norvaline: differs from valine in being 1 carbon longer instead of branched; RN given refers to (L)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

L-2-aminopentanoic acid : A 2-aminopentanoic acid that has S-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65098
CHEMBL ID55612
CHEBI ID18314
SCHEMBL ID38405
MeSH IDM0046787

Synonyms (58)

Synonym
AC-12879
norvaline, l-
valeric acid, 2-amino-
nsc-203786
norvaline
pentanoic acid, 2-amino-
CHEBI:18314 ,
(2s)-2-aminopentanoic acid
2s-amino-pentanoic acid
LMFA01100041
NVA ,
6600-40-4
l-norvaline
(s)-2-aminopentanoic acid
l-2-aminopentanoic acid
l-2-aminopentanoate
l-2-aminovaleric acid
C01826
l-norvaline, arginase inhibitor
DB04185
N-9040
9555A1CC-4DD7-41F1-9133-98A0F33A16A6
CHEMBL55612
(s)-2-aminovaleric acid
N0686
(2s)-2-aminopentanoic acid;l-norvaline
A835303
AKOS006240270
l(+)-norvaline
pentanoic acid, 2-amino-, (s)-
unii-a70uks48fe
nsc 203786
alpha-l-aminopentanoic acid
norvaline (van)
einecs 229-543-3
a70uks48fe ,
bdbm50357215
l-(+)-norvaline
h-nva-oh
AM20100599
l-.alpha.-aminovaleric acid
norvaline [who-dd]
2s-aminovaleric acid
norvaline [mi]
norvaline [inci]
(s)-(+)-2-aminopentanoic acid
SCHEMBL38405
mfcd00064421
SNDPXSYFESPGGJ-BYPYZUCNSA-N
(s)-2-amino-pentanoic acid
AC-31149
CS-D1371
HY-Y0399
Q418707
AS-13576
DTXSID701018015
EN300-66088
Z1033300662

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" It is well known that some NPAAs are toxic through their ability to mimic protein amino acids, either in protein synthesis or in other metabolic pathways, and this property is utilised by some plants to inhibit the growth of other plants or kill herbivores."( Cytotoxicity and mitochondrial dysfunction caused by the dietary supplement l-norvaline.
Rodgers, KJ; Samardzic, K, 2019
)
0.51

Bioavailability

ExcerptReferenceRelevance
"A decrease in nitric oxide (NO) bioavailability has been shown to cause hyperglycemia, type II diabetes mellitus (DM), and chronic cardio-metabolic complications."( Antihyperglycemic activity of L-norvaline and L-arginine in high-fat diet and streptozotocin-treated male rats.
Avtandilyan, N; Grigoryan, A; Javrushyan, H; Maloyan, A; Nadiryan, E, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
hypoglycemic agentA drug which lowers the blood glucose level.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
L-alpha-amino acid zwitterionZwitterionic form of an L-alpha-amino acid having an anionic carboxy group and a protonated amino group.
2-aminopentanoic acidAn alpha-amino acid that is valeric acid which is substituted at position 2 by an amino group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
monoatomic ion transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transportProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transportProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid import across plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proton transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
amino acid:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
proline:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
protein bindingProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-proline transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
lysosomal membraneProton-coupled amino acid transporter 1Homo sapiens (human)
endoplasmic reticulumProton-coupled amino acid transporter 1Homo sapiens (human)
plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
apical plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
vacuolar membraneProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID26797Partition coefficient (logP)1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID630741Inhibition of human PAT1-mediated L-[3H]proline uptake in human Caco2 cells after 10 mins by liquid scintillation counting2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Three-dimensional quantitative structure-activity relationship analyses of substrates of the human proton-coupled amino acid transporter 1 (hPAT1).
AID224503Effect on rate of GTP hydrolysis in the GTP binding protein ras p211998Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9
Prediction of the GTPase activities by using the semiempirical molecular orbital theory.
AID233318Bitter threshold value1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (146)

TimeframeStudies, This Drug (%)All Drugs %
pre-199039 (26.71)18.7374
1990's26 (17.81)18.2507
2000's23 (15.75)29.6817
2010's47 (32.19)24.3611
2020's11 (7.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.64%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other155 (99.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]